Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "SAP"

113 News Found

Cupid Partners with SAP to Implement Advanced ERP System, SAP S/4HANA Cloud
Digitisation | July 03, 2024

Cupid Partners with SAP to Implement Advanced ERP System, SAP S/4HANA Cloud

The integration of SAP S/4HANA Cloud will equip Cupid Limited with a comprehensive suite of integrated applications,


Suven to acquire a majority stake in CDMO player ‘Sapala Organics’
News | June 14, 2024

Suven to acquire a majority stake in CDMO player ‘Sapala Organics’

Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies


Ginkgo, SaponiQx to discover and manufacture next-gen vaccine adjuvants
Clinical Trials | February 17, 2024

Ginkgo, SaponiQx to discover and manufacture next-gen vaccine adjuvants

Adjuvants are components of vaccines that help to enhance the magnitude, breadth, and duration of the immune response to vaccination


Strides launches Icosapent Ethyl Acid Soft Gel capsules in partnership with Amneal
News | December 02, 2023

Strides launches Icosapent Ethyl Acid Soft Gel capsules in partnership with Amneal

The product has been in-licensed from Strides and will be commercialized by Amneal


Strides receives USFDA approval for Icosapent Ethyl capsules
Drug Approval | October 04, 2023

Strides receives USFDA approval for Icosapent Ethyl capsules

The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin


Strides receives USFDA approval for Icosapent Ethyl Capsules
Drug Approval | September 25, 2023

Strides receives USFDA approval for Icosapent Ethyl Capsules

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD)


Zydus receives final approval from the USFDA for Icosapent Ethyl Capsules
Drug Approval | April 24, 2023

Zydus receives final approval from the USFDA for Icosapent Ethyl Capsules

Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels


Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
News | December 05, 2022

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer


Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher
News | August 09, 2022

Margin disappointment continues for Lupin in Q1FY23 : Prabhudas Lilladher

Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.